In contrast, dual inhibition of MEK and PI3K/mTOR showed limited preclinical activity in a cohort of 40 RAS-mutant CRC PDXs, which is consistent with data from a phase I clinical trial [124,125,126]. Here, MAP2K7 is linked to colorectal carcinoma.